Replies to post #139284 on Biotech Values

[mcbio]

re: BLRX

McBio, are you still following this one? Any thoughts? How about Genisi? Anyone else?

I still keep an eye on BLRX, notwithstanding the bit of sour taste I still have in my mouth from how they handled the in-licensing of the HCV PI. That said, BLRX still has only about a $50M market cap with numerous shots on goal, the big one being the P2b trial for the potentially novel schizophrenia drug set to report in 2013. If they hit on those results in 2013, and they already have some degree of PoC from earlier results, I would certainly think that drug alone could support a much higher valuation. And they have an extensive pipeline behind that. So, sure they are on my watchlist. Don't know if I'll be taking a position though, due to lack of funds and other stocks that are a higher priority.